中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共4条，第1-4条 帮助

已选(0)清除 条数/页：   排序方式：
Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs) 期刊论文
ANNALS OF PALLIATIVE MEDICINE, 2021
作者:  Si, Jinfei;  Gu, Xiaodong;  Wang, Wenxian;  Ying, Shenpeng;  Song, Zhengbo
收藏  |  浏览/下载：95/0  |  提交时间：2022/02/14
Epidermal growth factor receptor (EGFR)  uncommon mutation  compound mutation  double uncommon mutation  lung adenocarcinoma (lung AC)  
Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions 期刊论文
THORACIC CANCER, 2020
作者:  Chen, Kaiyan;  Pan, Guoqiang;  Cheng, Guoping;  Zhang, Fanrong;  Xu, Yanjun;  Huang, Zhiyu;  Fan, Yun
收藏  |  浏览/下载：62/0  |  提交时间：2020/12/28
EGFR  HER2  immunotherapy  NSCLC  PD‐  L1  
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy 期刊论文
LUNG CANCER, 2020, 卷号: 142
作者:  Chen, Kaiyan;  Cheng, Guoping;  Zhang, Fanrong;  Zhu, Guanxia;  Xu, Yanjun;  Yu, Xiaoqing;  Huang, Zhiyu;  Fan, Yun
收藏  |  浏览/下载：59/0  |  提交时间：2020/11/26
Uncommon EGFR  Non-small cell lung cancer  PD-L1  T cell  Immunotherapy  
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29
-
收藏  |  浏览/下载：33/0  |  提交时间：2020/10/26
EGFR MUTATIONS  GEFITINIB TREATMENT  1ST-LINE TREATMENT  OPEN-LABEL  RARE  MULTICENTER  ERLOTINIB  GENE  CHEMOTHERAPY  EFFICACY  Non-small cell lung cancer  EGFR  uncommon mutation  target therapy